

What is claimed is:

1. Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.
2. Colistin sulphomethate sodium for the use as claimed in Claim 1 wherein the micronised powder is mixed with a carrier.
3. Colistin sulphomethate sodium for the use as claimed in Claim 2 wherein the carrier is lactose.
4. A composition comprising micronised colistin sulphomethate sodium as defined in Claim 1 and a carrier, in the absence of free liquid.
5. A composition as claimed in Claim 4 wherein the carrier is lactose.
6. A composition as claimed in Claim 4 or Claim 5 wherein the ratio of colistin sulphomethate sodium to carrier is from 5:1 to 1:2 by weight.
7. A composition as claimed in Claim 4 or Claim 5 wherein the ratio of colistin sulphomethate sodium to carrier is from 4:1 to 1:1 by weight.
8. The composition as claimed in any one of Claims 4 to 7 wherein at least 50% by volume of the carrier particles have an effective particle size in the range of 30-150 micrometers.
9. A composition as claimed in any one of Claims 4 to 8 wherein at least 50% by volume of the micronised colistin sulphomethate sodium has a particle diameter of less than 8 micrometers.

10. A composition as claimed in any one of Claims 4 to 9 wherein at least 25% of the particles of micronised colistin sulphomethate sodium have a diameter of less than 6 micrometers.
11. A composition as claimed in any one of Claims 4 to 10 wherein the micronised colistin sulphomethate sodium is prepared in the desired particle size range using a fluid energy mill.
12. A process for the preparation of a composition as claimed in any one of Claims 4 to 11 which comprises mixing micronised colistin sulphomethate sodium and a carrier.
13. A pharmaceutical dosage form suitable for use with a dry powder inhaler comprising micronised colistin sulphomethate sodium wherein at least 90% by volume of the particles have a diameter less than 10 micrometers or a composition according to any one of Claims 4 to 11 and a container, said dosage having a content of below 10 wt % water.
14. A pharmaceutical dosage form according to Claim 13 wherein the container is a hard gelatin capsule.
15. A capsule containing micronised colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers.
16. A capsule as claimed in Claim 15 containing from 10 to 200 milligrams of micronised colistin sulphomethate sodium.

17. A capsule as claimed in Claim 15 containing from 30 to 150 milligrams of micronised colistin sulphomethate sodium.
18. A capsule as claimed in any one of Claims 15 to 17 further comprising a carrier.
19. A capsule as claimed in Claim 18 when the carrier is lactose.
20. A capsule according to any one of Claims 15 to 19 which is opaque.
21. A capsule according to any one of Claims 15 to 19 or a composition according to any one of Claims 4 to 11 packed in an opaque container.
22. A capsule containing micronised colistin sulphomethate sodium when the micronised particles have a diameter of less than 10 micrometers, in unit dosage form.
23. A capsule according to any one of Claims 15 to 22 which additionally comprises a micronised bronchodilatory drug.
24. A capsule according to Claim 23 wherein the bronchodilatory drug is salbutamol.
25. A capsule according to Claim 23 or Claim 24 which comprises from 50 to 150 milligrams of colistin sulphomethate sodium and from 1 to 250 micrograms of bronchodilatory drug
26. Micronised particles of colistin sulphomethate sodium wherein at least 90% by volume of the micronised particles have a diameter of less than 10 micrometers for use in the treatment of a pulmonary infection by powder inhalation, wherein the colistin sulphomethate sodium is not separated into component form.

- add  $\rightarrow$

**SECRET**